Tag: Takeda Pharmaceutical
Takeda signs licensing deal for Hutchmed’s fruquintinib outside of China
Takeda Pharmaceutical will acquire an exclusive worldwide license, excluding China, of fruquintinib from Hutchmed (China) and its subsidiary Hutchmed to strengthen its oncology portfolio. Under ... Read More
Takeda gets QDENGA EC approval as dengue vaccine
Takeda has received the European Commission’s (EC) marketing authorization for the company’s dengue vaccine QDENGA (Dengue Tetravalent Vaccine ) (TAK-003). The QDENGA vaccine is indicated ... Read More
Strides Pharma Science gets FDA approval for Colchicine Tablets generic
Strides Pharma Science Limited said that its Singapore-based stepdown fully-owned subsidiary — Strides Pharma Global Pte. Limited has secured approval for Colchicine Tablets USP, 0.6 ... Read More
Takeda’s NINLARO fails to meet PFS primary endpoint in TOURMALINE-MM2 trial
Takeda Pharmaceutical said that the Phase 3 TOURMALINE-MM2 trial in newly diagnosed multiple myeloma patients for NINLARO (ixazomib) in addition to lenalidomide and dexamethasone failed ... Read More
Takeda to sell select non-core assets to Cheplapharm for $562m
Takeda Pharmaceutical has agreed to sell a portfolio of certain non-core prescription pharma products sold mainly in Europe and Canada to German pharma company Cheplapharm ... Read More
Takeda to divest consumer healthcare business to Blackstone for $2.3bn
Japanese pharma giant Takeda Pharmaceutical has agreed to sell its consumer healthcare business to Oscar A-Co KK, a company controlled by funds managed by The ... Read More
Takeda strikes deal to bring Novavax’ NVX‑CoV2373 COVID-19 vaccine to Japan
US-based pharma company Novavax and Takeda Pharmaceutical have joined forces for the development, manufacturing, and commercialization of NVX‑CoV2373, the former's COVID‑19 vaccine candidate, in Japan. ... Read More
Takeda gets extended EC approval for ADCETRIS in sALCL
Takeda Pharmaceutical has secured extended approval for ADCETRIS (brentuximab vedotin) in the European Union to include the treatment of previously untreated systemic anaplastic large cell ... Read More
Takeda Pharmaceutical to sell OTC and non-core products to Orifarm
Japan-based Takeda Pharmaceutical has agreed to sell a portfolio of 110 non-core over-the-counter (OTC) and prescription pharmaceutical products it sells in Europe along with a ... Read More
Takeda Pharmaceutical acquires celiac disease drug developer PvP Biologics
Takeda acquisition of PvP Biologics : Japanese pharma giant Takeda Pharmaceutical Company has acquired US-based celiac disease drug developer PvP Biologics in a deal worth ... Read More
